Acurx Pharmaceuticals, Inc. (ACXP)
1.43
+0.01
(+0.70%)
USD |
NASDAQ |
Sep 08, 16:00
1.435
0.00 (0.00%)
Pre-Market: 20:00
Acurx Pharmaceuticals Total Liabilities (Quarterly) : 2.833M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.833M |
| March 31, 2026 | 2.527M |
| December 31, 2025 | 2.421M |
| September 30, 2025 | 2.468M |
| June 30, 2025 | 2.592M |
| March 31, 2025 | 2.494M |
| December 31, 2024 | 3.243M |
| September 30, 2024 | 3.319M |
| June 30, 2024 | 3.153M |
| March 31, 2024 | 3.110M |
| December 31, 2023 | 3.042M |
| Date | Value |
|---|---|
| September 30, 2023 | 3.223M |
| June 30, 2023 | 3.019M |
| March 31, 2023 | 2.074M |
| December 31, 2022 | 2.062M |
| September 30, 2022 | 1.182M |
| June 30, 2022 | 0.4739M |
| March 31, 2022 | 0.633M |
| December 31, 2021 | 0.8439M |
| September 30, 2021 | 0.7124M |
| June 30, 2021 | 1.919M |
| March 31, 2021 | 0.5107M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 10.98M |
| Shareholders Equity (Quarterly) | 8.152M |
| Current Ratio | 3.878 |